The Tumor Immunotherapy and Microenvironment (TIME) group led by Dr. Bassam Janji at Luxembourg Institute of Health has previously identified autophagy as a resistance mechanism protecting cancer cells from immune surveillance. Sprint Bioscience, a Swedish drug discovery company has developed a selective Vps34 inhibitor (SB02024) with an excellent pharmacological profile. Following discussion during the Annual TRANSAUTOPHAGY Conference, held in Warsaw Poland, October 2016, Bassam Janji and Sprint Bioscience started a collaboration bridging together their respective competencies in tumor immunology, autophagy and drug development to investigate the impact of Vps34 inhibition on the improvement of the therapeutic benefit of immunotherapy.
COST (European Cooperation in Science and Technology) is a pan-European intergovernmental framework. Its mission is to enable break-through scientific and technological developments leading to new concepts and products and thereby contribute to strengthening Europe’s research and innovation capacities. www.cost.eu
COST is supported by EU Framework Programme Horizon 2020.
TRANSAUTOPHAGY COST ACTION
Neuroscience Institute, Faculty of Medicine Universitat Autónoma de Barcelona